• 提示：詳情請(qǐng)下載說(shuō)明書(shū)。

• 產(chǎn)品描述： LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer

• 靶點(diǎn)： Cdc7:3.3 nM (IC50);pMCM2:290 nM (IC50);CDK

• 體外研究：
  LY3177833 (10 μM; 4 days) increases SA-β-gal content in Hep3B cells. Western Blot Analysis Cell Line: Hep3B cells Concentration: 10 μM Incubation Time: 4 days Result: Increased the expression of human SA-β-gal.

• 體內(nèi)研究：
  LY3177833 (Example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dose-dependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation. Animal Model: Female athymic Balb/c nude mice (5-6 weeks old) with SW620 cells Dosage: 10.4 mg/kg, 20.8 mg/kg and 31.2 mg/kg Administration: Oral gavage; twice a day for 2 weeks Result: Showed dose dependent antitumor activity in SW620 mouse xenograft tumor model.

• 參考文獻(xiàn)：
  1. Robert Dean Dally, et al. CDC7 Inhibitors. Patent WO2014143601A1. 2. Li X, et al. First-generation species-selective chemical probes for fluorescence imaging of human senescence-associated β-galactosidase. Chem Sci. 2020 Jun 17;11(28):7292-7301.

• 溶解性： Soluble  in  DMSO

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	3.233 ml	16.166 ml	32.331 ml
  5 mM	0.647 ml	3.233 ml	6.466 ml
  10 mM	0.323 ml	1.617 ml	3.233 ml
  50 mM	0.065 ml	0.323 ml	0.647 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號(hào)：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *